Fuga Takahashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fuga Takahashi has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Kenichi Arai
Univ Toyama, Fac Med, Dept Clin Biomat Appl Sci, 2630 Sugitani, Toyama 9300194, Japan
1 shared publication - Praneel Patel
Department of Clinical Biomaterial Applied Science, Faculty of Medicine, University of Toyama, Toyama 930-8555, Japan
1 shared publication - Takahiro Kitsuka
Department of Clinical Biomaterial Applied Science, Faculty of Medicine, University of Toyama, Toyama 930-8555, Japan
1 shared publication
Latest Publications
- Open Access
- 10 February 2023
- Published by MDPI AG in Bioengineering
- Vol. 10 (2) , 237
The Exciting Realities and Possibilities of iPS-Derived Cardiomyocytes
Induced pluripotent stem cells (iPSCs) have become a prevalent topic after their discovery, advertised as an ethical alternative to embryonic stem cells (ESCs). Due to their ability to differentiate into several kinds of cells, including cardiomyocytes, researchers quickly realized the potential for differentiated cardiomyocytes to be used in the treatment of heart failure, a research area with few alternatives. This paper discusses the differentiation process for human iPSC-derived cardiomyocytes and the possible applications of said cells while answering some questions regarding ethical issues.
- 10 February 2023
- Published by MDPI AG in Bioengineering
- Vol. 10 (2) , 237
Open AccessThe Exciting Realities and Possibilities of iPS-Derived Cardiomyocytes
Induced pluripotent stem cells (iPSCs) have become a prevalent topic after their discovery, advertised as an ethical alternative to embryonic stem cells (ESCs). Due to their ability to differentiate into several kinds of cells, including cardiomyocytes, researchers quickly realized the potential for differentiated cardiomyocytes to be used in the treatment of heart failure, a research area with few alternatives. This paper discusses the differentiation process for human iPSC-derived cardiomyocytes and the possible applications of said cells while answering some questions regarding ethical issues.